The utility of leukergy test in gastroenteritis with Campylobacter in children
Abstract
Gastroenteritis with Campylobacter has proven in the last decade to be one of the most common causes of bacterial enteritis in children. Objectives. The objective of the current study was to highlight the usefulness of using the leukergy test, a test characterized by the aggregation capacity and increased adhesiveness of leukocytes in the case of bacterial infections, in order to establish as early as possible, the bacterial etiology of campylobacteriosis compared to the time it takes to gather other bacteriological evidence. Materials and methods. This paper was based on a single center prospective case-control study conducted between June 2020 and May 2021 at Ponderas Academic Hospital, which involved 45 children hospitalized with medium and severe forms of gastroenteritis with Campylobacter jejuni, and a control group of 40 children who are clinically and biologically healthy. The property of aggregation, adhesiveness of leukocytes in peripheral blood of the 85 children included in the research was studied using the leukergia test. The results of the leukergia test were subsequently compared with other acute phase reactants, collected from the same blood sample: total leukocyte count (WBCC), total neutrophil count (NEUT), C-reactive protein (CRP). Results. Sensitivity, Specificity and Positive Predictive Value had values of: 93.3%, 82.50%, 85.71% for leukergy (%); 93.3%, 85%, 87.5% for WBCC with normal values; 88.89%, 82.5%, 85.11% NEUT and 95.56%, 97.5%, 97.7% for CRP.…
How strong is the evidence?
Evidence Hub reads this as a case-control, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 85 participants or records.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.